Amarin commented that following this week’s European Society of Cardiology Congress in Munich, Germany, its landmark cardiovascular outcomes study, REDUCE-IT, is now likely to be the next large cardiovascular outcomes study to report results. As previously guided, top-line results from the REDUCE-IT study are expected to be reported before the end of September 2018. REDUCE-IT is evaluating the effect of Vascepa, administered at four grams per day, as an add-on to statin therapy, on major adverse cardiovascular events as compared to statin treated patients plus placebo. REDUCE-IT is the first cardiovascular outcomes study to be conducted in patients who despite low density lipoprotein cholesterol control have risk factors for cardiovascular disease, including elevated triglyceride levels. The company said that its REDUCE-IT study of Vascepa is noticeably different than the recently completed ASCEND trial presented today at ESC 2018. ASCEND studied a different drug in a different patient population.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.